What Effects do GLP-1Injections Have on Gastroparesis in Ehlers-Danlos Syndrome

(Unsplash Photo)

Gastroparesis, a condition marked by delayed stomach emptying, presents a significant challenge for many people with Ehlers-Danlos Syndrome (EDS). Managing this digestive issue is complex, especially when considering treatments that may affect gastrointestinal motility. GLP-1 receptor agonists have gained attention for their role in managing diabetes and weight loss, but their impact on gastroparesis in EDS patients raises important questions.

Gastroparesis and Ehlers-Danlos Syndrome

Ehlers-Danlos Syndrome is a group of connective tissue disorders characterized by joint hypermobility, skin elasticity, and tissue fragility. Many individuals with EDS also experience gastrointestinal complications, with gastroparesis being one of the more common and debilitating issues. Gastroparesis slows the movement of food from the stomach to the small intestine, causing symptoms such as:

• Nausea and vomiting

• Bloating and severe abdominal pain

• Early satiety (feeling full quickly)

• Constipation/diarrhea

• Acid Reflux/Belching frequently

• Malnutrition and weight loss

  
  

The underlying cause of gastroparesis in EDS is often linked to autonomic nervous system dysfunction and connective tissue abnormalities affecting the stomach muscles.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs primarily used to treat type 2 diabetes and obesity. Ozempic (semaglutide) is one such medication that mimics the action of the natural hormone GLP-1. It helps regulate blood sugar by:

• Stimulating insulin release

• Suppressing glucagon secretion

• Slowing gastric emptying

  
  

The slowing of gastric emptying is a key effect that helps control post-meal blood sugar spikes. However, this same effect can be problematic for people with gastroparesis.

How GLP-1 Medications Affect Gastroparesis in EDS

Because GLP-1 receptor agonists slow stomach emptying, they may worsen gastroparesis symptoms in some patients. For individuals with EDS, whose gastric motility is already compromised, this effect can lead to increased nausea, bloating, indigestion and discomfort.

Clinical Observations and Patient Reports

• Some patients with EDS and gastroparesis report worsening digestive symptoms after starting a GLP-1 medications.

• Others find that low doses or careful timing of medication can minimize side effects.

• There is limited formal research specifically on GLP-1 drugs in EDS-related gastroparesis, so much of the understanding comes from case reports and clinical experience.

  
  

Balancing Benefits and Risks

For people with type 2 diabetes or obesity who also have EDS and gastroparesis, the decision to use GLP-1 medications requires careful consideration:

• Blood sugar control: GLP-1 drugs can significantly improve glucose management, which is crucial for overall health.

• Weight management: These medications often help reduce appetite and promote weight loss, which may benefit EDS patients struggling with obesity-related complications.

• Gastroparesis symptoms: The risk of worsening digestive symptoms must be weighed against these benefits.

  
  

Healthcare providers may adjust doses, recommend alternative medications, or suggest additional treatments to manage gastroparesis symptoms alongside GLP-1 therapy.

Practical Tips for Managing Gastroparesis While Using GLP-1 Medications

If you have EDS and gastroparesis and are prescribed a GLP-1 medication, consider these strategies to reduce discomfort:

• Start with a low dose and increase gradually under medical supervision.

• Take medication with meals or at times that minimize symptom flare-ups.

• Follow a gastroparesis-friendly diet: small, frequent meals that are low in fat and fiber can help.

• Stay hydrated and monitor symptoms closely.

• Communicate regularly with your healthcare team about any changes in symptoms.

  
  

In some cases, additional treatments such as prokinetic agents (which stimulate stomach motility) may be necessary to counteract delayed gastric emptying.

The Need for More Research on GLP-1 Medications and Patients with Gastroparesis

Current knowledge about the interaction between GLP-1 medications and gastroparesis in EDS is limited. More clinical studies are needed to:

• Understand the extent to which GLP-1 drugs affect gastric emptying in EDS patients.

• Identify which patients are most at risk of worsening symptoms.

• Develop guidelines for safely using these medications in this population.

  
  

Until then, personalized care and close monitoring remain essential.

GLP-1 medications offer important benefits for managing diabetes and weight control, but their effect on gastric emptying can complicate gastroparesis in people with Ehlers-Danlos Syndrome. Patients and healthcare providers must work together to balance these factors, tailoring treatment plans to individual needs. If you have EDS and gastroparesis, discuss the potential risks and benefits of GLP-1 therapies with your doctor, and explore strategies to manage symptoms effectively. Staying informed and proactive can help improve quality of life while navigating these complex health challenges. Knowing risks prior to starting a GLP-1 helps identify symptoms if problems arise.